Table 1.
Characteristics of the patients with pSS
| Characteristics | Laboratory examination | ||||
|---|---|---|---|---|---|
| Age, mean ± SD, years | 50.58 ±11.30 | Cutaneous vasculitis, n (%) | 4 (6.7%) | UWSF* ≤0.1 ml/min, n (%) | 36 (60.0%) |
| Gender (female/male) | 57/3 | ILD*, n (%) | 18 (30.0%) | Schirmer test ≤5 mm/5min, n (%) | 30 (50.0%) |
| Duration, M (Q25, Q75)*, years | 2.50 (1.00, 5.75) | RTA*, n (%) | 8 (13.3%) | Ocular stain (+), n (%) | 37 (61.7%) |
| Ocular/oral symptoms, n (%) | 39 (65.0%) | PNS*, n (%) | 2 (3.3%) | High IgG, n (%) | 39 (65.0%) |
| Fever, n (%) | 3 (5.0%) | Hematological system | 34 (56.7%) | RF* (+) , n (%) | 25 (41.7%) |
| Lymphadenopathy, n (%) | 13 (21.7%) | Leucocytopenia , n (%) | 16 (26.7%) | Anti-SSA/Ro52 antibody (+), n (%) | 47 (78.3%) |
| Glandular swelling, n (%) | 3 (5.0%) | Anaemia, n (%) | 15 (25.0%) | Anti-SSA/Ro60 antibody (+), n (%) | 46 (76.7%) |
| Joint swelling/pain, n (%) | 10 (16.7%) | Thrombocytopenia, n (%) | 7 (11.7%) | Anti-SSB antibody (+), n (%) | 36 (60.0%) |
| Biopsy focus (+), n (%) | 40 (66.7%) | ||||
| ESSDAI* | |||||
| ESSDAI (1–4), n (%) | 17 (28.3%) | ||||
| ESSDAI (5–13), n (%) | 36 (60.0%) | ||||
| ESSDAI (≥ 14), n (%) | 7 (11.7%) | ||||
*ESSDAI European League Against Rheumatism Sjögren’s syndrome disease activity index, ILD interstitial lung disease, M median, pSS primary Sjogren's Syndrome, PVS peripheral nervous system, Q quartile, RF rheumatoid factor, RTA renal tubular acidosis, SD standard deviation, UWSF unstimulated whole salivary flows